CareDx Inc (CDNA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CareDx Inc (CDNA) has a cash flow conversion efficiency ratio of 0.072x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($30.60 Million) by net assets ($425.60 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of CareDx Inc for the company's overall valuation and market capitalisation.
CareDx Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how CareDx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CareDx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CareDx Inc ranked by their cash flow conversion efficiency. Explore CDNA cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GOLDEN AGRI-RES ADR/100
F:4G3
|
N/A |
|
Advanced Technology & Materials Co Ltd
SHE:000969
|
0.045x |
|
Sunway Construction Group Bhd
KLSE:5263
|
0.402x |
|
KEYMED BIOSCIENCES -0001
F:64Z
|
N/A |
|
American Eagle Outfitters Inc
NYSE:AEO
|
0.032x |
|
Danaos Corporation
NYSE:DAC
|
0.049x |
|
Chung-Hsin Electric & Machinery Mfg Corp
TW:1513
|
0.031x |
|
Jack Sewing
SHG:603337
|
0.054x |
Annual Cash Flow Conversion Efficiency for CareDx Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of CareDx Inc from 2012 to 2025. View CDNA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $303.10 Million | $42.03 Million | 0.139x | +37.93% |
| 2024-12-31 | $378.43 Million | $38.05 Million | 0.101x | +242.89% |
| 2023-12-31 | $261.33 Million | $-18.39 Million | -0.070x | -20.13% |
| 2022-12-31 | $430.91 Million | $-25.24 Million | -0.059x | -41.43% |
| 2021-12-31 | $465.88 Million | $-19.29 Million | -0.041x | -134.40% |
| 2020-12-31 | $277.68 Million | $33.43 Million | 0.120x | +530.45% |
| 2019-12-31 | $99.00 Million | $-2.77 Million | -0.028x | +33.04% |
| 2018-12-31 | $95.93 Million | $-4.01 Million | -0.042x | -101.74% |
| 2017-12-31 | $-5.95 Million | $-14.31 Million | 2.403x | +387.38% |
| 2016-12-31 | $19.76 Million | $-16.52 Million | -0.836x | -152.88% |
| 2015-12-31 | $29.49 Million | $-9.75 Million | -0.331x | -307.61% |
| 2014-12-31 | $41.30 Million | $-3.35 Million | -0.081x | -2338.51% |
| 2013-12-31 | $-150.67 Million | $-546.00K | 0.004x | -69.96% |
| 2012-12-31 | $-147.20 Million | $-1.78 Million | 0.012x | -- |
About CareDx Inc
CareDx, Inc. provides solutions for improving outcomes for transplant patients and advancing organ health in the United States and internationally. The company provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression profiling solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart tr… Read more